endocardial nitric oxide synthase and nitric oxide production, with consequent upregulation of prothrombotic plasminogen activator inhibitor-1, suggesting increased thrombogenicity. 14 Gene microarray analysis showed upregulation of procoagulant factor genes in AF patients, 15 and thrombosis-related genes are upregulated in a canine model of congestive heart failure (CHF)-induced atrial structural remodeling. 16 Despite the enormous clinical importance of AF-associated thromboembolism, there are no published direct experimental assessments of the influence of putative AF-related thrombosis-promoting conditions on atrial thrombus formation. This study aimed to establish whether AF-related remodeling enhances the risk of atrial thrombus formation. Specific objectives included determining whether AF-promoting remodeling (ATR-induced or CHF-induced) favors the formation of atrial thrombi, and determining whether persistent rapid atrial activation (AT or AF) interacts with previous atrial remodeling to promote thrombus formation. Because of the low occurrence rate of spontaneous thrombus formation, we used radiofrequency ablation (RFA) to produce thrombus formation to assess the prothrombotic tendencies of various AF-related paradigms. 17 
Methods
Detailed Methods are available in the online-only Data Supplement.
Experimental Groups
Animal handling procedures were approved by the local Animal Research Ethics Committee. Fifty-four mongrel dogs (weight, 20.7-38.2 kg) were studied in the following groups ( Figure 1 ): (1) normal control dogs kept in SR for 7 days before RFA and the 7-day post-RFA follow-up period (control group); (2) dogs with ATR induced by 7-day atrial tachypacing (ATR group); (3) dogs with CHF induced by ventricular tachypacing applied for a 14-day pre-RFA preparation and 7-day post-RFA follow-up period (CHF group); and (4) dogs with chronic AF (CAF) induced by long-term atrial tachypacing (CAF group). After the preparation periods, 4 RFA lesions were created in each atrium. Dogs were subjected to electrophysiological study (EPS) 7 days after RFA, followed by euthanasia, cardiac excision, and thrombus quantification. In ATR and CHF groups, half the dogs were subjected to atrial tachypacing during the 7-day post-RFA follow-up period (ATR-AT and CHF-AT subgroups), whereas the others were left in sinus node-driven atrial rhythm during 7-day post-RFA followup (ATR-SR and CHF-SR subgroups).
Animal Models
Atrial tachypacing and ventricular tachypacing were performed as previously described. 16, [18] [19] [20] Dogs were anesthetized with ketamine (5.3 mg/kg, intravenous), diazepam (0.25 mg/kg, intravenous), and isoflurane (1.5%). In ATR dogs, bipolar pacing leads were inserted into the right ventricular apex and right atrial appendage and connected to subcutaneous pacemakers (Vitatron). Atrioventricular block was created by His bundle RFA. The right ventricular demand pacemaker was programmed to 80 bpm. After 24-hour postoperative recovery, 7-day atrial tachypacing at 400 bpm was initiated. Atrial RFA was performed on day 7. In CHF dogs, a bipolar pacing lead was inserted into the right ventricular apex and connected to a pacemaker. After 24-hour recovery, 14-day ventricular tachypacing at 240 bpm was initiated. RFA was performed on day 14. In CAF dogs, a bipolar pacing lead was inserted into the right atrial appendage and connected to a pacemaker. Atrioventricular block was not created; digoxin (0.25 mg/day) was administered to control ventricular response. After 24-hour postoperative recovery, atrial tachypacing at 400 bpm was initiated. The electrocardiogram then was verified at least twice per week. Atrial tachypacing was continued for 35±3 days until the dogs had >24 hours of CAF. AF then was maintained until RFA (5±1 additional days). In all dogs, a bipolar pacing lead was inserted into the right atrial appendage for serial EPS.
Echocardiography
Transthoracic echocardiography was performed under sedation (Atravet 0.07 mg/kg; buprenorphine 0.009 mg/kg, intramuscularly) before RFA and at terminal study. All recordings were performed in SR except for the terminal study in CAF dogs, in which echocardiography was performed in AF to avoid directcurrent cardioversion-induced dislodging of the atrial thrombus. For details of echocardiographic measurements, see online-only Data Supplement. The average of 3 to 6 cardiac cycles was used for each measurement, with the operator blinded to treatment assignment.
EPS
Closed-chest EPS was performed before RFA and at terminal study for control, ATR, and CHF groups. During EPS, tachypacemakers were deactivated. In CAF dogs, AF was direct-currentcardioverted for the pre-RFA EPS, but cardioversion was not performed at terminal study to avoid thrombus dislodgment. EPS was performed in SR (and therefore was not performed at the terminal study in CAF dogs). Effective refractory period (longest premature coupling interval [S1S2] failing to capture) was measured in right atrial appendage (2×threshold-current, 2-ms pulses, 3 determinations) at basic cycle lengths of 150, 200, 250, 300, and 360 ms with 10 basic stimuli (S1s), followed by premature extrastimuli (S2s) with 5-ms decrements. AF was induced by 1-s to 10-s burst pacing; 10 Hz; 4× threshold current. Mean AF duration was based on 10 AF inductions for AF <20 min and 5 AF inductions for AF 20 to 30 min. Prolonged AF (>30 min) was terminated by cardioversion. If prolonged AF was induced twice, then no further AF induction was performed.
RFA
RFA was performed during SR in control, ATR-SR, and CHF-SR subgroups, during atrial tachypacing in ATR-AT and CHF-AT subgroups, and during AF in the CAF group. Dogs were anesthetized (morphine [ 
Blood Samples
Citrated blood samples from a femoral vein were obtained at the terminal study. Plasma was removed and stored at -80°C. The concentrations of a coagulation activation marker, thrombin-antithrombin complexes, and an inflammation marker, C-reactive protein, were analyzed by enzyme-linked immunosorbent assay.
Histology and Histochemistry
After animal euthanasia, hearts were removed, fixed in 10% formalin, and subjected to histological processing. Maximal length and width of ablation lesions were measured. Paraffin-embedded specimens were serially sectioned at a thickness of 6 µm. Thrombi were defined and quantified as described previously. 17 Personnel analyzing lesion morphometry were blinded to experimental group. Mean thrombus volume and total thrombus volume were calculated for each dog.
Data Analysis
Continuous variables are expressed as mean±SEM for normally distributed variables (Shapiro-Wilk test) or median and first and third quartile values (Q1-Q3)/minimum-maximum values for non-normal variables. Multiple group comparisons were obtained with 1-way ANOVA with Bonferroni-adjusted t tests (for normally distributed data) or Kruskal-Wallis test with Dunn multiple comparison test (for non-normally distributed data) for nonrepeated measures (main effect factor dog group). Repeated-measures analyses were performed for normally distributed data with 2-way ANOVA and Bonferroni-adjusted t tests. Two-tailed P<0.05 indicated statistical significance. The authors had full access to and take responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results

Electrophysiologic Characteristics
The electrophysiologic characteristics of each group of dogs after the pre-RFA preparation period are shown in Figure 2 . Data were not different between SR and AT subgroups in ATR and CHF dogs before RFA, and therefore are expressed per model in Figure 2 . Full data for all subgroups before RFA and at the terminal study are shown in online-only Data Supplement Figure  I . Atrial effective refractory period was significantly reduced in ATR and CAF groups and was slightly, but not significantly, longer in CHF vs control groups (Figure 2A ). The mean duration of AF induced by burst pacing during electrophysiological study was longer in ATR, CHF, and CAF groups compared with the control group ( Figure 2B ). At the terminal study (onlineonly Data Supplement Figure I ), SR maintenance for the 7-day post-RFA interval in the ATR-SR group (Group 2A in Figure 1 ) allowed for complete reversal of effective refractory period and AF-duration changes caused by ATR. Post-RFA atrial tachypacing in the CHF-AT group shortened the previously prolonged atrial effective refractory period back to control values and tended to further prolong AF duration. Electrophysiological values were not significantly different within groups between pre-RFA and terminal studies in ATR-AT and CHF-SR subgroups, and were consistent with previous work in the same models. 21 
Echocardiographic Characteristics
Selected echocardiographic characteristics of each primary group of dogs before RFA and at terminal study are shown in Figure 3 . Complete echocardiographic data for all subgroups are shown in online-only Data Supplement Table I . Data were not significantly different between SR and AT subgroups of ATR and CHF dogs before RFA. In CHF, left ventricular diastolic and systolic volumes were larger, and left ventricular ejection fraction was lower compared with controls both before RFA and at terminal study. Left ventricular ejection fraction was slightly but significantly lower, without significant left ventricular dilatation, in CAF. LA size was substantially larger and LA fractional area change was lower in CHF vs control groups. Late atrial-dependent ventricular filling (A)-wave velocity was lower and early/late ventricular filling velocity (E/A) ratio was higher in ATR group versus control group (no A-wave was present after RFA in the CAF group because echocardiograms were obtained in AF; onlineonly Data Supplement Table I ). Post-RFA SR reversed LA remodeling in ATR-SR, with statistical significance between pre-RFA and terminal studies observed in LA systolic and diastolic areas, A-wave velocity, and E/A ratio (online-only Data Supplement Table I ). In CHF-AT, post-RFA AT further increased LA diastolic size (diameter and area) and decreased LA contractility (fractional shortening and fractional area change) significantly, whereas A-wave velocity decreased and E/A ratio increased significantly (online-only Data Supplement Table I ). No images compatible with thrombus per se were obtained.
Plasma Thrombin-Antithrombin Complexes and C-Reactive Protein Concentrations
Plasma thrombin-antithrombin complexes and C-reactive protein concentrations for each group of dogs at the terminal 
Ablation Lesion and Thrombus Sizes
The characteristics of RFA lesions and thrombi are presented in the Table. Subgroup-based lesion characteristics in each region are shown in online-only Data Supplement Table II . The number of successfully performed ablation lesions and mean lesion area, depth, and volume did not differ among groups. More than 70% of lesions were associated with thrombus and there were no significant differences compared with controls in the prevalence or number of thrombi among groups. Representative examples of thrombus histopathology from a control and a CAF dog are shown in Figure 5A and 5B, respectively. Thrombi were clear and amenable to histomorphometric quantification; no systematic qualitative differences in thrombus histomorphology were seen. Mean thrombus size data are shown in Figure 5C . Representative examples of histopathology and mean thrombus size data from all subgroups are shown in online-only Data Supplement Figure III . There were no significant differences in total thrombus volume per dog among groups ( Figure 5C ). Similarly, ATR indicates atrial tachycardia remodeling; CAF, chronic atrial fibrillation; and CHF, congestive heart failure. There were no statistically significant differences for any groups vs control group for any of these variables studied.
there were no significant differences when thrombus volume was normalized to number of lesions per dog or lesion area (Table) . In addition, there were no specific atrial regions in which thrombus size differed (online-only Data Supplement Table II ). Thrombi formed only in RFA sites.
Discussion
Atrial thromboembolism is the most significant complication of AF. Based primarily on inferences from clinical observations, a variety of mechanisms have been suggested to contribute to AF-related thromboembolism. However, there are virtually no experimental data available about the basic factors governing atrial thrombus formation in AF models. Here, we examined the effects of a variety of AF-associated paradigms on atrial thrombus occurrence and volume. We found that, contrary to expectations based on suggestions in the literature, none of these paradigms promoted thrombus formation in our model.
Determinants of Atrial Thrombogenesis in AF
Atrial thrombi causing cardioembolic stroke are typically red cell-rich "red thrombi" typical of low-flow, stasis-associated thrombi, like those occurring in leg veins. 22, 23 Echocardiographic indices of LA stasis are useful predictors of thromboembolic risk in AF and are often relied on as key indicators of the safety of direct-current cardioversion. 24 Atrial stasis in AF has been suggested to be not only attributable to the rapid and disorganized rhythm per se but also attributable to atrial contractile abnormalities induced by the atrial remodeling resulting from AF.
11-13 AF-related remodeling causes atrial hypocontractility via multiple factors, including L-type Ca 2+ current reduction, impaired subcellular Ca 2+ signal transmission, and altered myofilament function associated with abnormal myosin and myosin-associated protein phosphorylation.
11-13
In addition to blood stasis, there is evidence that the other key factors of the Virchow triangle, endothelial thromboresistance and blood coagulability, are altered in AF and AF-related remodeling, and that these changes are important in atrial thromboembolism. 25 An association between increased C-reactive protein concentrations and AF occurrence suggests a possible inflammatory component. 26, 27 C-reactive protein associates with echocardiographic indices of atrial stasis, supporting an "inflammatory hypothesis" related to thrombogenic risk in AF. 27 These inflammatory processes, together with increased expressions of growth factors, such as tissue factor, vascular endothelial growth factor, and the vascular endothelial growth factor receptor sFlt-1, may contribute to endothelial thrombogenic dysfunction. [28] [29] [30] Upregulation of von Willebrand factor is compatible with AF-related thrombogenic endothelial dysfunction. 29 In atrially tachypaced pigs, nitric oxide synthase expression and nitric oxide production are downregulated, with associated upregulation of prothrombotic plasminogen activator inhibitor-1 in the LA endothelium.
14 Thrombomodulin and tissue factor pathway inhibitor are downregulated in the LA endothelium of atrially tachypaced rats. 30 CHF is a risk factor for AF-related thromboembolism. 31 The basis for this association is unknown, but CHF causes abnormal clotting properties, even in SR patients, 32 and promotes atrial dilation and contraction disturbances.
RFA damages endocardial endothelium and causes local inflammation, producing local thrombus formation. 17 Thromboembolic complications occur in approximately 0.8% of patients undergoing RFA, with the prevalence closer to 2% for RFA in the left heart. , respectively. C, Mean thrombus volumes in each group of dogs. Results are median, Q1-Q3 box plot; minimum and maximum value, whiskers. n=16, 16, 14, and 8 for CTL, atrial tachycardia remodeling (ATR), congestive heart failure (CHF), and CAF groups, respectively.
Novel Aspects and Potential Significance
There are no published experimental studies of the effect of atrial remodeling on atrial thrombus formation. Although previous studies point to an increased thrombotic risk based on changes in biomarkers of coagulation and inflammation, [26] [27] [28] [29] [30] direct prothrombotic effects have never been assessed. We designed this study to investigate the effects of AF-related remodeling on atrial thrombotic risk, considering many factors proposed in the literature to promote thrombogenesis in AF, such as ATR, CHF, atrial dilation, and AF itself. The electrophysiological changes in each subgroup are consistent with results of previous studies in the respective models. 21 We built into the design an analysis of both pre-RFA and post-RFA remodeling with the use of rhythm paradigms that incorporated SR or atrial tachypacing in a controlled way after the application of RFA. To our great surprise, none of the interventions we analyzed promoted atrial thrombus formation. Our observations challenge the widely believed notion that AF-associated remodeling directly promotes atrial thrombus formation.
Potential thrombogenic properties of the remodeled atrial milieu have important therapeutic implications. If, for example, atrial inflammation, oxidant stress, or deficient endothelial thromboprotection attributable to AF contributes to atrial thrombosis, then therapies directed against these changes and the underlying remodeling should protect against AF-related stroke and other complications. It is conceivable that such protection could be achieved with less associated risk than systemic anticoagulation, offering supplementary benefit to oral anticoagulants or a component of alternative therapy for patients at high risk for bleeding. Our results argue that additional experimental work is needed to directly establish the role, if any, of various atrial remodeling-related factors in AF-associated thromboembolism.
Considerations of the Model
We elected to use RFA to promote atrial thrombus formation. We reasoned that if any of the remodeling paradigms that we studied promote atrial thrombogenesis, then they would increase thrombus size and alter the thrombotic biomarkers that we studied. Our studies exclude such a prothrombotic state. Ideally, we would have liked to study spontaneous thrombus formation, but we anticipated a low prevalence of spontaneous thrombus formation, an expectation that was borne out by the lack of thrombi in atrial areas other than those exposed to RFA. Even in patients at highest risk, with CHADS 2 scores >5, annual thromboembolic rates of >6% per year have been reported, 34 although much higher rates of thromboembolic events have been reported in patients who were not anticoagulated after hospital discharge. 35 In patients with subtherapeutic anticoagulation before AF cardioversion, the prevalence of echocardiographically detectable thrombi is <10%. 36 Thus, spontaneous atrial thrombus formation may be difficult to observe in animal models that mimic human AF.
Our findings raise some interesting questions about the thromboembolic risk of RFA in AF ablation or in patients with AF. If AF-related remodeling causes a prothrombotic state, then RFA-related thromboembolic events would be more likely in patients undergoing RFA in the presence of the arrhythmia. Our results suggest that this may not be the case, a notion that should be amenable to testing in databases and clinical trials.
Like any experimental study, extrapolation of our findings to humans should be very cautious. Our models do not perfectly mimic any clinical situation, and the coagulation system of dogs may be different from that of humans. Our study was relatively short-term. Dogs were monitored for 7 days after RFA, and the longest remodeling interval (in CAF dogs) was 5 weeks. We elected to use relatively short-term models for practical reasons (limited dog-housing capacity), and because the previously published indirect experimental evidence for an effect of remodeling on AF-related thromboembolic risk derives from such short-term studies. [11] [12] [13] [14] 16 Although data to indicate that longer periods of AF-related remodeling might influence atrial thrombogenesis are lacking, this possibility cannot be excluded and should be assessed in future work. Nevertheless, because thromboembolism is the most important complication of AF and its underlying mechanistic determinants are incompletely understood, we feel that the present study is an important first step toward further critical experimental testing of widely held notions about the factors governing AF-related thrombus formation.
Other Possible Limitations
First, although no detectable symptomatic stroke was observed in this study, brain imaging analyses (eg, by magnetic resonance imaging or computed tomography) were not performed; therefore, the possibility of silent cerebral infarctions could not be excluded. Second, although excision of the heart was performed carefully, because transesophageal echocardiographic studies were not performed, undetected dislodgement of atrial thrombi conceivably could have occurred. Future work addressing both of these concerns would be of interest. Third, although the sheaths were flushed with heparinized saline, no other anticoagulation was used during the protocol. We cannot exclude the possibility that differences among groups would be evident only in anticoagulated models. Fourth, because of the relatively small numbers of animals in each group, we cannot exclude small differences among groups that escaped detection.
Conclusions
Atrial thrombus formation is not affected by a wide range of AF remodeling paradigms in dogs. These observations challenge the notion that AF-related remodeling per se directly produces a prothrombotic state. Further study in experimental and clinical models is needed to understand more precisely the basic mechanisms underlying AF-associated thromboembolism, the most important adverse clinical consequence of the arrhythmia.
